research use only
Cat.No.S3078
| Related Targets | Adrenergic Receptor Estrogen/progestogen Receptor GPR Androgen Receptor ACE RAAS Progesterone Receptor Opioid Receptor PGES THR |
|---|---|
| Other Glucocorticoid Receptor Inhibitors | Corticosterone AL082D06 (20S)-Protopanaxatriol Cortodoxone |
|
In vitro |
DMSO
: 104 mg/mL
(199.6 mM)
Ethanol : 18 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 521.04 | Formula | C28H37ClO7 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 5534-09-8 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | Beclometasone dipropionate,Beclovent,Beconase,Vancenase | Smiles | CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)Cl)O)C)C)OC(=O)CC | ||
| Targets/IC50/Ki |
Glucocorticoid receptor
|
|---|---|
| In vitro |
Beclomethasone dipropionate (BDP) is an anti-inflammatory corticosteroid available for the treatment of asthma and allergic rhinitis (AR). BDP is previously developed as aqueous nasal formulations for the treatment of AR. BDP is also available in dry nasal aerosol formulations as chlorofluoro carbon (CFC) metered-dose inhaler nasal sprays, but CFC-containing formulations have been withdrawn from the market and currently are not available.BDP hydrofluoroalkane (HFA) inhalation aerosol currently is available for patient use and indicated for the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older.BDP HFA nasal aerosol, an intranasal aerosol formulation, has been developed recently for the treatment of AR. |
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05352191 | Unknown status | Performance Detection|Doping |
Western Norway University of Applied Sciences|The Norwegian School of Sport Sciences|The Norwegian Doping Control Laboratory |
September 1 2022 | Phase 4 |
| NCT01697956 | Completed | Allergic Rhinitis |
Teva Branded Pharmaceutical Products R&D Inc. |
October 2012 | Phase 3 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.